Jeff Yass’s aTyr Pharma ATYR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$446K Sell
18,676
-2,993
-14% -$78.2K ﹤0.01% 10172
2026
Q1
$676K Buy
21,669
+2,550
+13% +$86.1K ﹤0.01% 8884
2025
Q4
$599K Buy
19,119
+15,952
+504% +$524K ﹤0.01% 8376
2025
Q3
$91.4K Sell
3,167
-3,183
-50% -$577K ﹤0.01% 11619
2025
Q2
$1.29M Sell
6,350
-36,977
-85% -$5.82M ﹤0.01% 6798
2025
Q1
$5.23M Buy
43,327
+23,631
+120% +$3.45M ﹤0.01% 3566
2024
Q4
$2.85M Buy
19,696
+16,365
+491% +$1.98M ﹤0.01% 4571
2024
Q3
$234K Buy
+3,331
New +$242K ﹤0.01% 10140
2023
Q3
– Sell
-1,166
Closed -$101K – 13169
2023
Q2
$101K Buy
+1,166
New +$102K ﹤0.01% 10943
2022
Q4
– Sell
-1,139
Closed -$137K – 13886
2022
Q3
$137K Sell
1,139
-24
-2% -$3.22K ﹤0.01% 11371
2022
Q2
$132K Buy
+1,163
New +$168K ﹤0.01% 11192
2021
Q4
– Sell
-2,045
Closed -$683K – 14051
2021
Q3
$743K Buy
2,045
+1,774
+655% +$424K ﹤0.01% 8344
2021
Q2
$53K Buy
+271
New +$46.2K ﹤0.01% 12285
2020
Q2
– Sell
-257
Closed -$29K – 11078
2020
Q1
$29K Buy
+257
New +$44.4K ﹤0.01% 9839
2019
Q1
– Sell
-177
Closed -$49K – 9997
2018
Q4
$49K Buy
177
+47
+36% +$15.7K ﹤0.01% 8490
2018
Q3
$59K Buy
+130
New +$56.9K ﹤0.01% 8797
2017
Q2
– Sell
-35
Closed -$68K – 9942
2017
Q1
$68K Buy
+35
New +$64K ﹤0.01% 8519

Other funds holding ATYR

Jeff Yass's ATYR Position: Q2 2026 in Review

Jeff Yass reduced its aTyr Pharma (ATYR) stake by 14% in Q2 2026, selling an estimated $78.2K and leaving 18,676 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #10172.

Jeff Yass first reported a position in ATYR in Q1 2017 and has held it in 17 quarters since. The position peaked at $5.23M in Q1 2025. 87 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Jeff Yass held 18,676 shares of aTyr Pharma worth $446K as of Q2 2026.
  • Jeff Yass sold 2,993 aTyr Pharma shares in Q2 2026, an estimated $78.2K.
  • aTyr Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10172 holding.
  • Jeff Yass first reported a position in aTyr Pharma in Q1 2017 and has held it in 17 quarters since.
  • Jeff Yass's aTyr Pharma position peaked at $5.23M in Q1 2025.
  • 87 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.